APICES Acknowledged for its Remarkable Role in CANTABRICO Clinical Trial
APICES CRO is pleased to announce its contribution to the CANTABRICO study. This is a Phase IIIb clinical trial in Small Cell Lung Cancer (SCLC), recently featured in the Elsevier Lung Cancer Journal.
The study evaluates first-line treatment in patients with extensive-stage SCLC (ES-SCLC) using an initial regimen of up to six cycles of durvalumab plus platinum-etoposide, followed by maintenance with durvalumab. The results demonstrate the feasibility of this approach. It also provides additional options for daily clinical management depending on patient characteristics.
APICES contributed to the study through start-up, coordination, project management, monitoring, data management, statistical analysis and medical editorial assistance. The work of Sofía Morante, Ana Moreno, Laura Redondo, Susana Vara, Fernando Rico-Villademoros, and Juan Luis Sanz, along with the broader Spanish team, has been instrumental in the success of this project.
We also acknowledge AstraZeneca Spain and Dr. Dolores Isla for the collaboration and opportunity to contribute to this important study advancing treatment options in oncology.
For further information about the CANTABRICO Clinical Trial, please read the full scientific publication following the link: Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial – Lung Cancer
